Delirium symptoms duration and mortality in SARS-COV2 elderly: results of a multicenter retrospective cohort study.
COVID
Delirium
Delirium symptoms
Elderly
SARS-COV2
Journal
Aging clinical and experimental research
ISSN: 1720-8319
Titre abrégé: Aging Clin Exp Res
Pays: Germany
ID NLM: 101132995
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
03
04
2021
accepted:
29
05
2021
pubmed:
28
6
2021
medline:
28
7
2021
entrez:
27
6
2021
Statut:
ppublish
Résumé
Since the occurrence of the SARS-COV2 pandemic, there has been an increasing interest in investigating the epidemiology of delirium. Delirium is frequent in SARS-COV2 patients and it is associated with increased mortality; however, no information is available on the association between delirium duration in SARS-COV2 patients and related outcomes. The aim of this study is to investigate the association between the duration of delirium symptoms and in-hospital mortality in older patients with SARS-COV2 infection. Retrospective cohort study of patients 65 years of age and older with SARS-CoV 2 infection admitted to two acute geriatric wards and one rehabilitation ward. Delirium symptoms duration was assessed retrospectively with a chart-based validated method. In-hospital mortality was ascertained via medical records. A total of 241 patients were included. The prevalence of delirium on admission was 16%. The median number of days with delirium symptoms was 4 (IQR 2-6.5) vs. 0 (IQR 0-2) in patients with and without delirium on admission. In the multivariable Cox regression model, each day with a delirium symptom in a patient with the same length of stay was associated with a 10% increase in in-hospital mortality (Hazard ratio 1.1, 95% Confidence interval 1.01-1.2; p = 0.03). Other variables associated with increased risk of in-hospital death were age, comorbidity, CPAP, CRP levels and total number of drugs on admission. The study supports the necessity to establish protocols for the monitoring and management of delirium during emergency conditions to allow an appropriate care for older patients.
Sections du résumé
BACKGROUND
BACKGROUND
Since the occurrence of the SARS-COV2 pandemic, there has been an increasing interest in investigating the epidemiology of delirium. Delirium is frequent in SARS-COV2 patients and it is associated with increased mortality; however, no information is available on the association between delirium duration in SARS-COV2 patients and related outcomes.
AIMS
OBJECTIVE
The aim of this study is to investigate the association between the duration of delirium symptoms and in-hospital mortality in older patients with SARS-COV2 infection.
METHODS
METHODS
Retrospective cohort study of patients 65 years of age and older with SARS-CoV 2 infection admitted to two acute geriatric wards and one rehabilitation ward. Delirium symptoms duration was assessed retrospectively with a chart-based validated method. In-hospital mortality was ascertained via medical records.
RESULTS
RESULTS
A total of 241 patients were included. The prevalence of delirium on admission was 16%. The median number of days with delirium symptoms was 4 (IQR 2-6.5) vs. 0 (IQR 0-2) in patients with and without delirium on admission. In the multivariable Cox regression model, each day with a delirium symptom in a patient with the same length of stay was associated with a 10% increase in in-hospital mortality (Hazard ratio 1.1, 95% Confidence interval 1.01-1.2; p = 0.03). Other variables associated with increased risk of in-hospital death were age, comorbidity, CPAP, CRP levels and total number of drugs on admission.
CONCLUSIONS
CONCLUSIONS
The study supports the necessity to establish protocols for the monitoring and management of delirium during emergency conditions to allow an appropriate care for older patients.
Identifiants
pubmed: 34176083
doi: 10.1007/s40520-021-01899-8
pii: 10.1007/s40520-021-01899-8
pmc: PMC8234761
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2327-2333Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Ann Intern Med. 1990 Dec 15;113(12):941-8
pubmed: 2240918
J Am Geriatr Soc. 2021 Feb;69(2):293-299
pubmed: 33411332
J Hosp Med. 2012 May-Jun;7(5):450-3
pubmed: 22173963
J Am Med Dir Assoc. 2009 Jun;10(5):330-4
pubmed: 19497545
Am J Respir Crit Care Med. 2009 Dec 1;180(11):1092-7
pubmed: 19745202
J Am Geriatr Soc. 2005 Feb;53(2):312-8
pubmed: 15673358
Age Ageing. 2021 May 5;50(3):733-743
pubmed: 33951145
J Psychosom Res. 2021 Feb;141:110350
pubmed: 33401078
Psychosomatics. 2009 May-Jun;50(3):234-8
pubmed: 19567762
J Am Geriatr Soc. 2014 Jul;62(7):1335-40
pubmed: 24890941
J Psychosom Res. 2015 Oct;79(4):281-7
pubmed: 26282373
J Am Med Dir Assoc. 2014 May;15(5):349-54
pubmed: 24566447
J Am Med Dir Assoc. 2016 Sep 1;17(9):828-33
pubmed: 27346621
J Am Med Dir Assoc. 2016 Mar 1;17(3):214-9
pubmed: 26585091
Age Ageing. 2014 Jul;43(4):496-502
pubmed: 24590568
Lancet. 2014 Mar 8;383(9920):911-22
pubmed: 23992774
Aging Clin Exp Res. 2015 Aug;27(4):523-31
pubmed: 25556562
Age Ageing. 2020 Oct 23;49(6):923-926
pubmed: 32821901
BMC Med. 2016 Jul 18;14:106
pubmed: 27430902
Eur Geriatr Med. 2020 Oct;11(5):857-862
pubmed: 32666303
J Gerontol A Biol Sci Med Sci. 2019 May 16;74(6):910-916
pubmed: 29982365